Analyst Research

Report Title Price
Provider: Stock Traders Daily
$20.00
Provider: Thomson Reuters Stock Report
$25.00
Provider: Jefferson Research
$20.00
Provider: S&P Capital IQ – STARS Reports
$127.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

FDA approves Glaxosmithkline Plc's Flonase Allergy Relief for sale over-the-counter in The United States


Thursday, 24 Jul 2014 01:32pm EDT 

Glaxosmithkline plc:Announces that the U.S. Food and Drug Administration (FDA) has approved Flonase Allergy Relief.Flonase Allergy Relief containing the No. 1 prescribed allergy treatment ingredient1, as an over-the-counter (OTC) treatment for temporary relief of the symptoms of hay fever or upper respiratory allergies.2.Flonase Allergy Relief is the first and only over-the-counter nasal spray indicated for relief of all nasal and eye-related allergy symptoms3,4including runny nose, sneezing, itchy nose5-7, nasal congestion8-11and itchy and watery eyes.